#USA #Marlborough #Boston Scientific #Dan Brennan #Jon Monson

Boston Scientific Leadership Transition

Boston Scientific Corporation has announced a significant leadership change as Chief Financial Officer (CFO) Dan Brennan plans his retirement after nearly three decades of dedicated service to the company. Starting at the end of June 2025, Brennan will step down from his role, paving the way for Jon Monson, currently serving as the senior vice president of Investor Relations, to succeed him.

This transition reflects not just a change in personnel but also a continuation of Boston Scientific's strong financial leadership. Mike Mahoney, the company's chairman and CEO, expressed gratitude towards Brennan, acknowledging his impactful contributions which have been pivotal in reshaping Boston Scientific's financial strategies and overall performance during his tenure.

Brennan's remarkable journey includes being instrumental in various strategic initiatives that have enhanced the company's market position and operational excellence. He has particularly excelled in overseeing the financial performance of Boston Scientific since he was appointed CFO in 2014. His work fostered a culture of strong values and financial stewardship, playing an essential role in the company's success over the years.

As Brennan prepares to exit, he will not disappear entirely from the company. He is set to continue as a senior advisor until early October 2025, providing his expertise during a critical transition period. This advisory role aims to ensure that Jon Monson, as the new CFO, can smoothly assume his responsibilities and drive forward the company's finance initiatives.

Who is Jon Monson?

Jon Monson is no stranger to Boston Scientific, having been with the company for over 25 years. His extensive experience within the corporate structure includes various leadership roles in finance, higher-level positions that have equipped him well for his new role as CFO. He previously served as the global controller and chief accounting officer, successfully guiding the company through challenging financial periods, including the disruptions caused by the 2020 pandemic. This broad financial experience and strategic vision are expected to serve him well as he leads Boston Scientific into the next chapter.

Monson will not only lead all company functions related to finance, including global controllership and corporate finance, but will also focus on talent development within the finance organization. As Mahoney noted, Monson's strategic mindset and commitment to high performance and innovation are qualities that make him an ideal candidate for the position.

The Future of Boston Scientific

As Boston Scientific looks ahead, the company emphasizes a commitment to innovation in medical technology that has characterized its operations for over 45 years. The leadership transition comes at a time when Boston Scientific continues to strive to meet the healthcare needs of patients worldwide, aiming to enhance the quality and effectiveness of healthcare delivery across various medical disciplines.

Brennan's departure and Monson's succession mark a pivotal point in Boston Scientific’s trajectory. The leadership change is expected not only to reinforce the company's values and operational strengths but also to inspire confidence among stakeholders as it navigates the future healthcare landscape.

In conclusion, as Dan Brennan retires, the legacy of his leadership will undoubtedly influence Jon Monson’s tenure as CFO. With a solid foundation, Monson is poised to uphold the momentum created under Brennan's guidance while steering Boston Scientific toward continued financial growth and innovative advancements in medical technology.

For more details about Boston Scientific and its innovative contributions to healthcare, please visit Boston Scientific's official website and stay connected through their social media platforms.